Relmada Therapeutics, Inc. RLMD Payments to Acquire Short-Term Investments
Payments to Acquire Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireShortTermInvestments.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s payments to acquire short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s payments to acquire short-term investments?
- Relmada Therapeutics, Inc. (RLMD) reported payments to acquire short-term investments of $149.52M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s payments to acquire short-term investments changed year-over-year?
- Relmada Therapeutics, Inc.'s payments to acquire short-term investments increased by 30544.1% year-over-year, from $487.92K to $149.52M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s payments to acquire short-term investments?
- Over 3 years (2022 to 2025), Relmada Therapeutics, Inc.'s payments to acquire short-term investments has grown at a 21.0% compound annual growth rate (CAGR), from $47.29M to $83.83M.